NASDAQ
Total Transactions
7
5 buys /2 sells
Shares Acquired
23,558.52
Transactions: 5•Avg: 4,711.7
Shares Disposed
43,442
Transactions: 2•Avg: 21,721
Net Activity
-19,883.48
Net Buying•Ratio: 250%
Q4 2025(Current) | 23,558.52 | 43,442 | -19,883.48 | 250.00% |
Q3 2025 | 211,302.87 | 438,458 | -227,155.13 | 77.78% |
Q2 2025 | 37,652.42 | 36,257 | +1,395.42 | 600.00% |
Q1 2025 | 1,316,209.91 | 743,267 | +572,942.91 | 84.38% |
Q4 2024 | 70,378.32 | 68,835 | +1,543.32 | 400.00% |
This table shows insider trading activity by quarter. A ratio > 100% indicates insiders acquired more shares than they disposed of during the period, which is generally considered a bullish signal.
• Most recent data for Q4 2025
Acquired vs Disposed Shares
Net Distribution: 19,883.48 shares•Acquired/Disposed Ratio: 250%
Net Activity | |||||
|---|---|---|---|---|---|
DJ Duato Joaquin | Director, officer: ceo and chairman of the board | 7 | 489,209 | 382,500 | +106,709 |
WJJ Wolk Joseph J | Officer: exec vp, cfo | 12 | 135,030 | 44,184 | +90,846 |
ST Schmid Timothy | Officer: evp, ww chair, medtech | 14 | 59,054 | 8,349 | +50,705 |
FE Forminard Elizabeth | Officer: executive vp, general counsel | 5 | 66,398 | 21,091 | +45,307 |
RJC REED JOHN C | Officer: evp, innovative medicine, r&d | 9 | 142,296 | 98,836 | +43,460 |
This table shows the trading activity of the most active company insiders. Positive net activity (buying more than selling) is often considered a bullish signal.
2025-12-09 | Director | Purchase | 185.53 | $0 | $0 | 5,058.07 | |
2025-12-09 | Director | Purchase | 247.38 | $0 | $0 | 14,153.12 | |
2025-12-09 | Director | Purchase | 154.61 | $0 | $0 | 331.23 | |
2025-11-26 | Director | Purchase | 1,250 | $206.15 | $257,687.5 | 1,848.51 | |
2025-10-17 | Officer: evp, innovative medicine, r&d | Sale | 21,721 | $157.92 | $3,430,180.32 | 43,442 |
This table displays recent Form 4 filings showing transactions by company insiders. SEC rules require insiders to report their transactions within two business days.
WEA Woods Eugene A. | Director | Dec 11, 2025 | |
HMA HEWSON MARILLYN A | Director | Dec 11, 2025 | |
PDE Pinto Daniel E | Director | Dec 11, 2025 | |
MJG MORIKIS JOHN G | Director | Dec 1, 2025 | |
RJC REED JOHN C | Officer: evp, innovative medicine, r&d | Oct 20, 2025 |
Net change in shares shown on right
No price data available for this timeframe.